As of May 28, 2025, Bergenbio ASA (BGBIO.OL) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Bergenbio ASA's Forward P/E to Peers
To better understand Bergenbio ASA's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Bergenbio ASA (BGBIO.OL) | - |
| Bioventix PLC (BVXP.L) | 1858.44 |
| Oryzon Genomics SA (ORY.MC) | 150.74 |
| Arcticzymes Technologies ASA (AZT.OL) | 89.32 |
| Orphazyme A/S (ORPHA.CO) | 16.18 |
| OSE Immunotherapeutics SA (OSE.PA) | 14.53 |
Compared to its competitors, Bergenbio ASA's Forward P/E is difficult to compare due to insufficient data.